YD BIO LTD Soars 40% on Nasdaq Debut Backed by $13.2M PIPE Financing

Introduction

YD BIO LTD (NASDAQ: YDES) is a biotechnology company focusing on DNA methylation-based cancer detection and developments in ophthalmology and regenerative medicine. As of September 3, 2025, its share price stood at $19.16, reflecting a 40.37% increase on a trading volume of 183,717 shares. The company completed a business combination with Breeze Holdings Acquisition Corp. and began trading on the Nasdaq Global Market on August 29, 2025, under the ticker symbols “YDES” (common shares) and “YDESW” (warrants).

Corporate Structure

YD BIO LTD operates as a publicly listed entity, with ordinary shares (par value $0.0001) and warrants registered under SEC Form 8-A12B on August 20, 2025. The leadership includes Dr. Ethan Shen (Founder, Chairman) and Dr. J. Douglas Ramsey (CEO of Breeze, now CEO of YD BIO LTD). According to LinkedIn data, the company employs between 11 and 50 staff, with expertise in molecular diagnostics, stem cell-based therapies, and clinical trial support. Its intellectual property portfolio includes:

• 11 licensed patents
• 12 pending patent applications
• 17 awards and publications
• 3 industry certifications

Biotechnology by Sangharsh Lohakare

Recent Developments

• September 25, 2024: Breeze Holdings Acquisition Corp. announced a definitive merger agreement with YD Biopharma Limited, with an anticipated pro forma enterprise value of nearly $700 million, targeting a listing on the Nasdaq Capital Market by early 2025.
• August 14, 2025: Breeze shareholders approved the business combination.
• August 15, 2025: SEC Form 6-K disclosed $13.2 million in PIPE financing commitments related to the merger.
• August 20, 2025: Registration of ordinary shares and warrants under Section 12(b) of the Exchange Act occurred.
• August 28, 2025: SEC certification (Form CERT) was issued, confirming the approval of YD BIO LTD’s securities for listing.
• August 29, 2025: Trading commenced on the Nasdaq Global Market; the PIPE offering and cash released from the trust generated more than $11.5 million to support operations.
• Planned 2025: Launch of a laboratory-developed test for recurrent breast cancer, alongside continued clinical development of pancreatic cancer methylation assays.
• Planned 2027: Initiation of clinical trials evaluating exosome-based contact lenses and artificial tears in ophthalmology.

Financial and Strategic Analysis

YD BIO LTD has strengthened its financial position through PIPE financing of $13.2 million and more than $11.5 million from merger proceeds. The company's strategy focuses on partnerships with EG BioMed and 3D Global Biotech to:

• Develop non-invasive DNA methylation diagnostics for early detection and monitoring of several cancers.
• Advance stem cell- and exosome-based ophthalmic therapies targeting dry eye syndrome, glaucoma, and corneal injury.
• Provide investigational drugs and ancillary materials for global pharmaceutical trials.

The approvals and registrations confirmed in August 2025 represent significant compliance milestones. The stock's 40.37% increase on September 3, 2025, indicates investor interest in the company's recent developments and its expanding product pipeline.

Market Position and Industry Context

YD BIO LTD operates within the growing sectors of molecular diagnostics and regenerative medicine. Its emphasis on DNA methylation assays aligns it with specialized oncology diagnostics firms, while its exosome-based ophthalmology programs aim to meet existing demands within eye care. The public listing on the Nasdaq Global Market enhances the company's capital access and visibility to biotech investors. Strategic partnerships with established biopharmaceutical companies and licensing agreements support YD BIO LTD’s capability to expand its offerings across multiple healthcare markets.

tl;dr

YD BIO LTD completed its merger with Breeze Holdings and began trading on Nasdaq on August 29, 2025. SEC filings in August confirmed the registration of shares and warrants and the company secured $13.2 million in PIPE financing, as well as over $11.5 million in merger proceeds. The stock increased by 40.37% on September 3, 2025. The company plans to launch breast cancer monitoring tests in 2025 and initiate ophthalmology exosome-based trials in 2027, leveraging partnerships and its patent portfolio to develop next-generation diagnostics and therapies.